162489-71-6

Upstream product

• 869186-47-0 (2-(2-(3-(S)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-hydroxypropyl)phenyl)-2-propoxy)tetrahydropyran 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 1000788-70-4 1-(((1-(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-((1-tetrahydropyranyloxy)-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropyl acetate 
• 1000788-71-5 2-[(1(R)-(3-((E)-2-(7-chloroquinolin-2-yl)ethenyl)phenyl)-3-(2-(1-(tetrahydropyran-2-yloxy)-1-methylethyl)phenyl)propyl)thiomethyl]-2-cyclopropylacetic acid 
• 158966-92-8 montelukast 
• 151767-02-1 Montelukast sodium 
• 1003002-65-0 (1-[(1(R)-(3-((E)-2-(7-chloroquinolin-2-yl)ethenyl)phenyl)-3-(2-(1-(tetrahydropyran-2-yloxy)-1-methylethyl)phenyl)propyl)thiomethyl]cyclopropyl)acetonitrile 

Relevant academic research and scientific papers

And Menlust sodium process for the preparation of intermediates

The invention relates to a method suitable for preparing montelukast sodium and intermediate 2-(3(S)-(3-(2-(7-chlorine-2-quinolyl) vinyl) phenyl)-3-hydroxypropyl) phenyl)-2-propoxy) tetrahydropyrane (intermediate 3) of the montelukast sodium in a large scale. According to the method, 7-chloroquinaldine and 3-cyanobenzaldehyde are used as starting raw materials, 2-(3-(3-(2-(7-chlorine-2-quinolyl) vinyl) phenyl)-3-oxopropyl) phenyl)-2-propoxy) tetrahydropyrane (intermediate 2) is obtained by six steps of reaction, then intermediate 3 with ee more than 99% and yield more than 90% is obtained by chiral reduction, and the montelukast sodium with high optical purity and high chemical purity is obtained by the intermediate 3 through four steps of reaction.

Process for the Preparation of Leukotriene Receptor Antagonist (Montelukast Sodium)

The present invention relates to an improved process for the preparation of [R-(E)]-1-[[[1-[3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-cyclopropaneacetic acid, monosodium salt of Formula (I).

AN IMPROVED PROCESS FOR THE PREPARATION OF LEUKOTRIENE RECEPTOR ANTAGONIST (MONTELUKAST SODIUM)

The present invention relates to an improved process for the preparation of [R-(E)]-1-[[[1-[3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-cyclopropaneacetic acid, monosodium salt of Formula (I).